According to reports, the British Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the new crown oral drug molnupiravir developed by Merck (MRK.US) and Ridgeback Biotherapeutics. According to a statement from Merck and Ridgeback, MHRA has approved its new crown oral drug molnupiravir for the treatment of patients with mild to moderate new crowns.
It is reported that in a previous interim analysis of a phase 3 clinical trial involving patients with mild to moderate new crowns, Merck’s drug molnupiravir can reduce the risk of hospitalization or death by about 50%.
As of press time, Merck & Co. rose 1.67% before the market to $90.16.